TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

NCT05091723 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

Interventions

DRUG: Nezulcitinib (TD-0903) Dose A
DRUG: Nezulcitinib (TD-0903) Dose B

Sponsor

Theravance Biopharma